Fig. 2
Comparison of high content imaging (HCI) and FLAR endpoints for generating potency data. A Table of pEC50 values for legacy and developmental anti-malarials tested. pEC50 is the negative log of potency in M (ie a pEC50 of 6 = an EC50 of 1 µM and a pEC50 of 9 = an EC50 of 1 nM). Values are the average and S.D. from two independent experiments (runs). Anti-malarial potencies are grouped by those active in both runs, those active in only one run or producing poor curve fits, and those inactive at the highest dose tested in both runs. eEF2, elongation Factor 2 inhibitor; DHODH, dihydroorotate dehydrogenase inhibitor, PI(4)K, phosphatidylinositol-4-OH kinase inhibitor; 8-AQ, 8-aminoquinoline, 4-AQ, 4-aminoquinoline; DHA, dihydroartemisinin. The “Target or Mechanism” column provides a reference for the possible or demonstrated mode of action and is not meant to be exhaustive or conclusive. B Plot of potency values obtained from the HCI versus FLAR endpoints. Line represents a simple linear regression (Y = 0.9919*X + 0.06728, R2 = 0.9863). C Plot of potency values obtained from FLAR endpoint and those reported using a luciferase protocol in a 1536-well plate format [17]. Line represents a simple linear regression (Y = 0.8275*X + 0.6979, R2 = 0.7546). B, C Points and bars represent the average and S.D. of the pEC50’s calculated from two independent experiments for the HCI and FLAR endpoints